Patents by Inventor Anlai Wang

Anlai Wang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7902205
    Abstract: The present invention relates to purinone derivatives which are agonists of the HM74a receptor. Further provided are compositions and methods of using the compounds herein, and their pharmaceutically acceptable salts for the treatment of disease.
    Type: Grant
    Filed: September 25, 2008
    Date of Patent: March 8, 2011
    Assignee: Incyte Corporation
    Inventors: Chu-Biao Xue, Brian Metcalf, Anlai Wang, Changsheng Zheng, Ganfeng Cao, Ke Zhang
  • Patent number: 7863285
    Abstract: The present invention relates to purinone derivatives which are agonists of the HM74a receptor. Further provided are compositions and methods of using the compounds herein, and their pharmaceutically acceptable salts for the treatment of disease.
    Type: Grant
    Filed: September 25, 2008
    Date of Patent: January 4, 2011
    Assignee: Incyte Corporation
    Inventors: Chu-Biao Xue, Brian Metcalf, Anlai Wang, Changsheng Zheng, Ganfeng Cao, Ke Zhang
  • Patent number: 7678798
    Abstract: The present invention relates to compounds of Formula I: wherein variable substituents are defined herein, that modulate the activity of or bind to chemokine receptors such as CCR5. In some embodiments, the compounds of the invention are selective for CCR5. The compounds can be used, for example, to treat diseases associated with chemokine receptor expression or activity such as inflammatory diseases, immune diseases and viral infections.
    Type: Grant
    Filed: April 12, 2005
    Date of Patent: March 16, 2010
    Assignee: Incyte Corporation
    Inventors: Chu-Biao Xue, Ganfeng Cao, Taisheng Huang, Lihua Chen, Ke Zhang, Anlai Wang, David Meloni, Rajan Anand, Joseph Glenn, Brian W. Metcalf
  • Publication number: 20090286792
    Abstract: The present invention relates to 3-cycloalkylaminopyrrolidine derivatives of the formula I: (wherein R1, R2, R3, R4, R5, R6, R7, X, Y and Z are as defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of chemokine receptors and more specifically as modulators of the CCR2 and/or CCR5 receptor. The compounds and compositions of the invention may bind to chemokine receptors, e.g., the CCR2 and/or CCR5 chemokine receptors, and are useful for treating diseases associated with chemokine, e.g., CCR2 and/or CCR5, activity, such as atherosclerosis, restenosis, lupus, organ transplant rejection and rheumatoid arthritis.
    Type: Application
    Filed: November 19, 2008
    Publication date: November 19, 2009
    Inventors: Chu-Biao Xue, Brian W. Metcalf, Amy Qi Han, Darius J. Robinson, Changsheng Zheng, Anlai Wang, Yingxin Zhang
  • Publication number: 20090286774
    Abstract: The present invention relates to purinone derivatives which are agonists of the HM74a receptor. Further provided are compositions and methods of using the compounds herein, and their pharmaceutically acceptable salts for the treatment of disease.
    Type: Application
    Filed: November 3, 2008
    Publication date: November 19, 2009
    Applicant: INCYTE CORPORATION
    Inventors: Changsheng ZHENG, Chu-Biao XUE, Ganfeng CAO, Michael XIA, Anlai WANG, Hai Fen YE, Brian METCALF
  • Patent number: 7576089
    Abstract: The present invention relates to 3-cycloalkylaminopyrrolidine derivatives of the formula I: (wherein R1, R2, R3, R4, R5, R6, R7, X, Y and Z are as defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of chemokine receptors and more specifically as modulators of the CCR2 and/or CCR5 receptor. The compounds and compositions of the invention may bind to chemokine receptors, e.g., the CCR2 and/or CCR5 chemokine receptors, and are useful for treating diseases associated with chemokine, e.g., CCR2 and/or CCR5, activity, such as atherosclerosis, restenosis, lupus, organ transplant rejection and rheumatoid arthritis.
    Type: Grant
    Filed: December 16, 2004
    Date of Patent: August 18, 2009
    Inventors: Chu-Biao Xue, Brian W. Metcalf, Amy Qi Han, Darius J. Robinson, Changsheng Zheng, Anlai Wang, Yingxin Zhang
  • Publication number: 20090197887
    Abstract: The present invention relates to compounds of Formula I: wherein variable substituents are defined herein, that modulate the activity of or bind to chemokine receptors such as CCR5. In some embodiments, the compounds of the invention are selective for CCR5. The compounds can be used, for example, to treat diseases associated with chemokine receptor expression or activity such as inflammatory diseases, immune diseases and viral infections.
    Type: Application
    Filed: April 13, 2009
    Publication date: August 6, 2009
    Inventors: Chu-Biao XUE, Ganfeng CAO, Taisheng HUANG, Lihua CHEN, Ke ZHANG, Anlai WANG, David MELONI, Rajan ANAND, Joseph GLENN, Brian W. METCALF
  • Publication number: 20090088446
    Abstract: The present invention relates to purinone derivatives which are agonists of the HM74a receptor. Further provided are compositions and methods of using the compounds herein, and their pharmaceutically acceptable salts for the treatment of disease.
    Type: Application
    Filed: September 25, 2008
    Publication date: April 2, 2009
    Applicant: INCYTE CORPORATION
    Inventors: Chu-Biao XUE, Brian METCALF, Anlai WANG, Changsheng ZHENG, Ganfeng CAO, Ke ZHANG
  • Patent number: 7511050
    Abstract: The present invention relates to purinone derivatives which are agonists of the HM74a receptor. Further provided are compositions and methods of using the compounds herein, and their pharmaceutically acceptable salts for the treatment of disease.
    Type: Grant
    Filed: June 22, 2007
    Date of Patent: March 31, 2009
    Assignee: Incyte Corporation
    Inventors: Changsheng Zheng, Chu-Biao Xue, Ganfeng Cao, Michael Xia, Anlai Wang, Hai Fen Ye, Brian Metcalf
  • Publication number: 20090076269
    Abstract: The present invention relates to purinone derivatives which are agonists of the HM74a receptor. Further provided are compositions and methods of using the compounds herein, and their pharmaceutically acceptable salts for the treatment of disease.
    Type: Application
    Filed: September 25, 2008
    Publication date: March 19, 2009
    Applicant: Incyte Corporation
    Inventors: Chu-Biao XUE, Brian METCALF, Anlai WANG, Changsheng ZHENG, Ganfeng CAO, Ke ZHANG
  • Patent number: 7462624
    Abstract: The present invention relates to purinone derivatives which are agonists of the HM74a receptor. Further provided are compositions and methods of using the compounds herein, and their pharmaceutically acceptable salts for the treatment of disease.
    Type: Grant
    Filed: June 22, 2007
    Date of Patent: December 9, 2008
    Assignee: Incyte Corporation
    Inventors: Chu-Biao Xue, Brian Metcalf, Anlai Wang, Changsheng Zheng, Ganfeng Cao, Ke Zhang
  • Publication number: 20080045555
    Abstract: The present invention relates to purinone derivatives which are agonists of the HM74a receptor. Further provided are compositions and methods of using the compounds herein, and their pharmaceutically acceptable salts for the treatment of disease.
    Type: Application
    Filed: June 22, 2007
    Publication date: February 21, 2008
    Applicant: Incyte Corporation
    Inventors: Chu-Biao Xue, Brian Metcalf, Anlai Wang, Changsheng Zheng, Ganfeng Cao, Ke Zhang
  • Publication number: 20080045554
    Abstract: The present invention relates to purinone derivatives which are agonists of the HM74a receptor. Further provided are compositions and methods of using the compounds herein, and their pharmaceutically acceptable salts for the treatment of disease.
    Type: Application
    Filed: June 22, 2007
    Publication date: February 21, 2008
    Applicant: Incyte Corporation
    Inventors: Changsheng Zheng, Chu-Biao Xue, Ganfeng Cao, Michael Xia, Anlai Wang, Hai Ye, Brian Metcalf
  • Publication number: 20050261310
    Abstract: The present invention relates to compounds of Formula I: wherein variable substituents are defined herein, that modulate the activity of or bind to chemokine receptors such as CCR5. In some embodiments, the compounds of the invention are selective for CCR5. The compounds can be used, for example, to treat diseases associated with chemokine receptor expression or activity such as inflammatory diseases, immune diseases and viral infections.
    Type: Application
    Filed: April 12, 2005
    Publication date: November 24, 2005
    Inventors: Chu-Biao Xue, Ganfeng Cao, Taisheng Huang, Lihua Chen, Ke Zhang, Anlai Wang, David Meloni, Rajan Anand, Joseph Glenn, Brian Metcalf
  • Publication number: 20050192302
    Abstract: The present invention relates to 3-cycloalkylaminopyrrolidine derivatives of the formula I: (wherein R1, R2, R3, R4, R5, R6, R7, X, Y and Z are as defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of chemokine receptors and more specifically as modulators of the CCR2 and/or CCR5 receptor. The compounds and compositions of the invention may bind to chemokine receptors, e.g., the CCR2 and/or CCR5 chemokine receptors, and are useful for treating diseases associated with chemokine, e.g., CCR2 and/or CCR5, activity, such as atherosclerosis, restenosis, lupus, organ transplant rejection and rheumatoid arthritis.
    Type: Application
    Filed: December 16, 2004
    Publication date: September 1, 2005
    Inventors: Chu-Biao Xue, Brian Metcalf, Amy Han, Darius Robinson, Changsheng Zheng, Anlai Wang, Yingxin Zhang
  • Publication number: 20040110287
    Abstract: The present invention provides improved methods of differentiating insulin+, glucose responsive islet-like structures from insulin− cells. The invention further provides methods for using insulin+, glucose responsive islet-like structures, as well as the insulin+, glucose responsive cells which comprise said islet-like clusters.
    Type: Application
    Filed: July 29, 2003
    Publication date: June 10, 2004
    Applicant: ES Cell International Pte Ltd.
    Inventors: Diana Clarke, Josephine S. D'Alessandro, Kuanghui Lu, Anlai Wang